BIND Biosciences Secures $12.4M in Series C-1 Financing

BIND Biosciences, Inc., a Cambridge, MA-based biopharmaceutical company developing targeted polymeric nanoparticle-based therapeutics that deliver high drug concentrations to diseased cells and tissues, has secured $12.4m in a Series C-1 financing.

Investors include all of BIND’s existing venture partners Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments, a new backer, Endeavour Vision, as well as private investors.

In January 2010, the company announced that it had secured an $11m Series C financing.

BIND’s Medicinal NanoengineeringTM approach enables the development of targeted polymeric nanoparticle-based therapeutics that deliver high drug concentrations to diseased cells and tissues, resulting in increased efficacy and reduced toxicity of existing and new drug compounds.

The new capital will be used to conduct initial clinical trials on the company’s lead product candidate, BIND-014, a nanoparticle cancer therapeutic targeted to a clinically-validated solid tumor antigen, and to advance a second product candidate toward the clinic.

29/06/2010